4.10.19.6Vertical

Spinal Cord Stimulation Programs

Physicians implanting and managing neuromodulation therapy.

Market snapshot

These figures describe Pain Management & Interventional Pain (4.10.19), the segment that Spinal Cord Stimulation Programs sits within. They are not figures for Spinal Cord Stimulation Programs on its own.

FragmentationConsolidatingEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so pain management is not separately sized.

Business model & economics

Revenue model

Procedure-driven interventional-pain reimbursement

Key economics

Recurring revenue
Moderate

chronic-pain management recurs

EBITDA margin
18–28% with ancillaries
Capex intensity
Moderate

Characteristics

  • Shift toward interventional, non-opioid pain treatment.
  • ASC and neuromodulation ancillaries drive economics.
  • Regulatory sensitivity around opioid prescribing.

M&A deal context

Deal activityModerate

Who’s acquiring

  • PE-backed pain platforms
  • Specialty MSO consolidators
  • ASC-aligned acquirers

What’s driving deals

  • Roll-up for interventional and ASC economics.
  • Chronic-pain and non-opioid-treatment demand.
  • Regulatory scrutiny shaping the specialty.

Find Spinal Cord Stimulation Programs acquisition targets

Search Acquisera’s index for companies classified under Spinal Cord Stimulation Programs (4.10.19.6) and build a targeted deal pipeline.

Search companies